China NMPA Approves NUZYRA® As A Category 1 Innovative Drug For The Treatment Of Patients With Community-Acquired Bacterial Pneumonia (CABP) And Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Published by The Street By GlobeNewswire NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as